FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and pharmaceutics, namely to cationic lipids of structural formula (1) for nucleic acid delivery, a method for production thereof, their use for delivery of nucleic acids into mammalian cells in vitro and in vivo. Disclosed versions of cationic lipids, as well as lipid particles based thereon, can be used to develop preventive and therapeutic preparations based on RNA. In general formula (1), where R is primary alkyl groups with chain length from 7 to 17 carbon atoms, Q is linker group of structure -C(O)NH-, or -C(O)O-, or -OC(O)-, X is an amino group or a dimethylamino group.
EFFECT: use of the group of inventions provides the creation of a cationic lipid which is capable of forming lipid particles in a complex with nucleic acid and providing its effective delivery both in vitro and in vivo.
13 cl, 14 dwg, 4 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRINUCLEOTIDE CAPPING REAGENT, METHOD FOR ITS PREPARATION AND USE | 2024 |
|
RU2829515C1 |
| mRNA-BASED IMMUNOBIOLOGICAL AGENT FOR PREVENTION OF DISEASES CAUSED BY TICK-BORNE ENCEPHALITIS VIRUS | 2024 |
|
RU2823754C1 |
| mRNA-BASED VECTOR FOR INCREASED TARGET PROTEIN PRODUCTION IN MAMMALIAN CELLS (VARIANTS) | 2022 |
|
RU2792231C1 |
| IMMUNOBIOLOGICAL AGENT FOR THERAPY OF ONCOLOGICAL DISEASES BASED ON mRNA VECTOR | 2024 |
|
RU2828631C1 |
| METHOD FOR FORMING IMMUNE SURVEILLANCE SYSTEM FOR TUMOUR CELLS IN MAMMAL BODY | 2024 |
|
RU2828654C1 |
| IONISABLE CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY | 2023 |
|
RU2823298C1 |
| IONIZABLE LIPIDS AND COMPOSITIONS THEREOF IN FORM OF NANOPARTICLES | 2020 |
|
RU2836646C1 |
| RNA PARTICLES INCLUDING POLYSARCOZINE | 2019 |
|
RU2792644C2 |
| METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | 2012 |
|
RU2647476C2 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING A COMPLEX IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS AND INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2836687C1 |
